A selective MAO-B inhibitor formulated to manage Parkinson's symptoms by alleviating stiffness and intended to support motor function in combination with levodopa.
Mechanism of Action
It selectively inhibits the enzyme MAO-B, which breaks down dopamine in the brain. This increases the amount and duration of dopamine activity, improving movement control.
Route of Administration
Oral
Onset Time
Variable
Duration
24 hours
Contraindications
Severe heart disease, Use of meperidine, Use of other MAOIs, Allergy to selegiline
Severe Adverse Events
Severe hypertensive crisis, Serotonin syndrome, Severe orthostatic hypotension
Information for Eldepryl is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
